Long COVID symptoms in SARS–CoV–2–positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study
Background: Many adolescents have been affected by the COVID-19 pandemic either directly by being infected with the virus or indirectly by lockdowns and restrictions influencing normal living. We aimed to investigate health, including symptoms of long COVID, in adolescents (aged 15-18 years) who tested positive for SARS-CoV-2 compared with a control group.
Methods: LongCOVIDKidsDK was a national, cross-sectional study carried out in Denmark, which included SARS-CoV-2-positive adolescents and matched controls. All Danish adolescents aged 15-18 years with a positive SARS-CoV-2 test during the period Jan 1, 2020, to July 12, 2021, and a control group matched (1:4) by age and sex were sent a survey from July 20, 2021. Participants had until Sept 15, 2021, to respond. Symptoms associated with COVID-19, school attendance, and health-related quality of life were investigated using ancillary questions and validated questionnaires (Paediatric Quality of Life Inventory [PedsQL] and Children’s Somatic Symptoms Inventory-24 [CSSI-24]). Statistical analyses included descriptive statistics and logistic regression. This study is registered at ClinicalTrials.gov, NCT04786353.
Findings: 24 315 adolescents with a positive SARS-CoV-2 test (case group) and 97 257 matched controls were invited to participate. 3013 matched controls were excluded because of suspected SARS-CoV-2 infection. 6630 (27·3%) responded in the case group and 21 640 (22·3%) responded and were eligible to participate in the control group. Across both groups, median age was 17·6 years (IQR 16·4-18·5), 16 277 (57·6%) of 28 270 responders were female, and 11 993 (42·4%) were male. Participants in the case group had greater odds of having at least one long COVID symptom lasting at least 2 months compared with the control group (3159 [61·9%] vs 12 340 [57·0%], odds ratio 1·22 [95% CI 1·15-1·30]; p<0·0001). Participants in the case group reported significantly lower symptom scores (ie, less somatic distress) on the CSSI-24 than in the control group: mean 10·7 (SD 11·4, median 7·0 [IQR 2·0-15·0]) versus 11·9 (10·6, 9·0 [4·0-17·0]; p<0·0001). Participants in the case group had better quality of life scores on the PedsQL than in the control group: physical functioning mean score 88·7 (SD 13·9, median 93·8 [IQR 84·4-100·0]) versus 86·5 (14·3, 90·6 [81·3-96·9]; p<0·0001); emotional functioning 77·1 (20·3, 80·0 [65·0-95·0]) versus 71·7 (21·4, 75·0 [60·0-90·0]; p<0·0001); social functioning 93·1 (12·5, 100·0 [90·0-100·0]) versus 88·4 (16·2, 95·0 [80·0-100·0]; p<0·0001); and school functioning 66·9 (22·5, 65·0 [60·0-85·0]) versus 62·9 (22·1, 65·0 [50·0-80·0]; p<0·0001). More participants in the case group than in the control group reported 16 or more sick days (1205 [18·2%] vs 2518 [11·6%]; p<0·0001) and 16 or more days of school absence (695 [10·5%] vs 1777 [8·2%]; p<0·0001).
Interpretation: Participants with SARS-CoV-2-positive tests had more long-lasting symptoms and sick leave, whereas participants in the control group had more short-lasting symptoms and worse quality of life. Knowledge of long COVID in adolescents is important to guide clinical recognition and management of this condition.
Funding: AP Møller and Chastine McKinney Møller Foundation.
A case-control study on the severity postpartum depression among COVID19 positive mother
Background: COVID19 pandemic has caused a variety of psychological problems including panic disorder, anxiety and depression. It is also associated with adverse psychological outcomes in pregnant women. The aim of this study was to compare the severity of postpartum depression in pregnant women with and without COVID-19 during the coronavirus epidemic.
Methods: This case-control study was performed on 102 pregnant women referred to the hospitals of (XXX). Using questionnaire, consisting of demographic and maternal data (age, number of pregnancies, type of delivery, history of any disease, history of drug use, breastfeeding experience, separation of mother from infant due to coronavirus) and score from Edinburgh postnatal depression scale (EPDS) score data from all the participants obtained and analyzed statistically using SPSSv23.
Results: The results showed that the mean EPDS score in COVID-positive mothers was 26.64 and in COVID-negative mothers was 24.76, which was statistically significant, p < 0.001. The score did not vary among the two group with respect to age group and type of delivery method. The score was significantly higher among the women with 3-4 pregnancies.
Conclusion: COVID-positive status is associated with increased postnatal depression among women. Perinatal and postnatal psychological consultancy is required in such patients along with monitoring of maternal and neonate physical and mental health.
SARS-CoV-2 ORF8 Positive Control |
|||
| MBS5401325-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 ORF8 Positive Control |
|||
| MBS5401325-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 ORF10 Positive Control |
|||
| MBS5401321-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 ORF10 Positive Control |
|||
| MBS5401321-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 ORF3a Positive Control |
|||
| MBS5401322-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 ORF3a Positive Control |
|||
| MBS5401322-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 ORF7a Positive Control |
|||
| MBS5401324-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 ORF7a Positive Control |
|||
| MBS5401324-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 Nucleocapsid Positive Control |
|||
| MBS5401320-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 Nucleocapsid Positive Control |
|||
| MBS5401320-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 envelope protein Positive Control |
|||
| MBS5401318-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 envelope protein Positive Control |
|||
| MBS5401318-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 surface glycoprotein Positive Control |
|||
| MBS5401326-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 surface glycoprotein Positive Control |
|||
| MBS5401326-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
SARS-CoV-2 membrane glycoprotein Positive Control |
|||
| MBS5401319-5Applications | MyBiosource | 5Applications | 335 EUR |
SARS-CoV-2 membrane glycoprotein Positive Control |
|||
| MBS5401319-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
|||
| NATFRC-6C | Zeptometrix | 6 x 0.5mL | 240 EUR |
SARS-COV-2 NP Monclonal Antibody (IgG/IgM Positive Control) |
|||
| MBS2567076-1mL | MyBiosource | 1mL | 875 EUR |
SARS-COV-2 NP Monclonal Antibody (IgG/IgM Positive Control) |
|||
| MBS2567076-5x1mL | MyBiosource | 5x1mL | 3900 EUR |
SARS-COV-2 Spike Monoclonal Antibody (IgG/IgM Positive Control) |
|||
| MBS2567075-1mL | MyBiosource | 1mL | 875 EUR |
SARS-COV-2 Spike Monoclonal Antibody (IgG/IgM Positive Control) |
|||
| MBS2567075-5x1mL | MyBiosource | 5x1mL | 3900 EUR |
SARS-CoV-2 Spike RBD HEK293 Cell Lysate (WB positive control) |
|||
| MBS8119857-INQUIRE | MyBiosource | INQUIRE | Ask for price |
SARS-CoV Spike/S1 HEK293 Cell Lysate (WB positive control) |
|||
| MBS8115894-03mg | MyBiosource | 0.3mg | 280 EUR |
SARS-CoV Spike/S1 HEK293 Cell Lysate (WB positive control) |
|||
| MBS8115894-5x03mg | MyBiosource | 5x0.3mg | 1205 EUR |
SARS-CoV Spike/RBD HEK293 Cell Lysate (WB positive control) |
|||
| MBS8115895-03mg | MyBiosource | 0.3mg | 280 EUR |
SARS-CoV Spike/RBD HEK293 Cell Lysate (WB positive control) |
|||
| MBS8115895-5x03mg | MyBiosource | 5x0.3mg | 1205 EUR |
SARS-CoV-2 (2019-nCoV) Spike Insect Cell Lysate (WB positive control) |
|||
| MBS8119649-03mg | MyBiosource | 0.3mg | 280 EUR |
SARS-CoV-2 (2019-nCoV) Spike Insect Cell Lysate (WB positive control) |
|||
| MBS8119649-5x03mg | MyBiosource | 5x0.3mg | 1205 EUR |
Case-<em>control</em> study to estimate odds of death within <em>2</em>8 days of <em>positive</em> test for <em>SARS</em>-<em>CoV</em>-<em>2</em> prior to vaccination for residents of long-term care facilities in England, <em>2</em>0<em>2</em>0-<em>2</em>0<em>2</em>1
Background: Persons living in long-term care facilities (LTCFs) are presumed to be at higher risk of adverse outcomes from SARS-CoV-2 infection due to increasing age and frailty, but the magnitude of increased risk is not well quantified.
Methods: After linking demographic and mortality data for cases with confirmed SARS-CoV-2 infection between March 2020 and January 2021 in England, a random sample of 6000 persons who died and 36 000 who did not die within 28 days of a positive test was obtained from the dataset of 3 020 800 patients. Based on an address-matching process, the residence type of each case was categorised into one of private home and residential or nursing LTCF. Univariable and multivariable logistic regression analysis was conducted.
Results: Multivariable analysis showed that an interaction effect between age and residence type determined the outcome. Compared with a 60-year-old person not living in LTCF, the adjusted OR (aOR) for same-aged persons living in residential and nursing LTCFs was 1.77 (95% CI 1.21 to 2.6, p=0.0017) and 3.95 (95% CI 2.77 to 5.64, p<0.0001), respectively. At 90 years of age, aORs were 0.87 (95% CI 0.72 to 1.06, p=0.21) and 0.74 (95% CI 0.61 to 0.9, p=0.001), respectively. The model had an overall accuracy of 94.2% (94.2%) when applied to the full dataset of 2 978 800 patients.
Conclusion: This study found that residents of LTCFs in England had higher odds of death up to 80 years of age. Beyond 80 years, there was no difference in the odds of death for LTCF residents compared with those in the wider community.